A study of combination Bicalutamide and Raloxifene for patients with castration-resistant prostate Cancer
Background Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β,
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
TH Ho, R Nunez-Nateras, YX Hou… - Clinical …, 2017 - mayoclinic.elsevierpure.com
A study to evaluate the toxicity of combination bicalutamide and raloxifene was conducted in
patients with prostate cancer. No grade 3 or 4 adverse events occurred, and no dose …
patients with prostate cancer. No grade 3 or 4 adverse events occurred, and no dose …
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
TH Ho, R Nunez-Nateras, YX Hou, AH Bryce… - Clinical Genitourinary …, 2017 - infona.pl
Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β, and estrogen-
based therapies have shown activity in preclinical studies. Raloxifene, a selective ER …
based therapies have shown activity in preclinical studies. Raloxifene, a selective ER …
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
TH Ho, R Nunez-Nateras, YX Hou… - Clinical …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β,
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
[引用][C] A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
TH Ho, R Nunez-Nateras, YX Hou, AH Bryce… - Clinical Genitourinary …, 2017 - cir.nii.ac.jp
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant
Prostate Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
Prostate Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.
TH Ho, R Nunez-Nateras, YX Hou… - Clinical Genitourinary …, 2016 - europepmc.org
Background Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β,
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
TH Ho, R Nunez-Nateras… - Clinical …, 2017 - clinical-genitourinary-cancer.com
Background Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β,
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a …
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
TH Ho, R Nunez-Nateras, YX Hou, AH Bryce… - Clinical Genitourinary …, 2017 - infona.pl
Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β, and estrogen-
based therapies have shown activity in preclinical studies. Raloxifene, a selective ER …
based therapies have shown activity in preclinical studies. Raloxifene, a selective ER …